Cyrus Pipeline
Program | MOA | Indication(s) | Discovery | Lead Optimization | Development Candidate | IND-Enabling |
Next-Gen IdeS CYR212/241 | Enhanced IgG protease | Autoimmunity (multiple) | ✓ | |||
Next-Gen IdeS CYR212/241 | Enhanced IgG protease |
Gene Therapy (multiple) | Partnering by indication | ✓ | ||
Next-Gen IL-22 | IL-22 Pathway Agonist | Multiple – autoimmune and metabolic | ✓ | |||
Next-Gen IL-15 | Activation of Tumor Infiltrating Teff and NK cells | Multiple – solid & hematologic tumors | ✓ | |||
sACE2.v2-Fc Fusion | SARS-CoV2 receptor decoy | COVID-19 therapy and prophylaxis | Partner evaluation in progress | ✓ | ||
PDGFR⍺-Fc Fusion | hCMV receptor decoy | hCMV Infection | ✓ | |||
Next-Gen IL-6 | IL-6 Pathway agonist | Metabolic | ✓ |
INTERESTED IN
PARTNERING WITH US ON
PROTEIN THERAPEUTICS?
*These programs, which include various aspects of protein design have a common core, which is deimunization of the infused protein
#These programs include multiple design elements and are not focused on deimmunzation